JP2015515459A5 - - Google Patents

Download PDF

Info

Publication number
JP2015515459A5
JP2015515459A5 JP2015500854A JP2015500854A JP2015515459A5 JP 2015515459 A5 JP2015515459 A5 JP 2015515459A5 JP 2015500854 A JP2015500854 A JP 2015500854A JP 2015500854 A JP2015500854 A JP 2015500854A JP 2015515459 A5 JP2015515459 A5 JP 2015515459A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
minutes
glp
lubricant
hydroxybenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015500854A
Other languages
English (en)
Japanese (ja)
Other versions
JP6356660B2 (ja
JP2015515459A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/055363 external-priority patent/WO2013139695A1/en
Publication of JP2015515459A publication Critical patent/JP2015515459A/ja
Publication of JP2015515459A5 publication Critical patent/JP2015515459A5/ja
Application granted granted Critical
Publication of JP6356660B2 publication Critical patent/JP6356660B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015500854A 2012-03-22 2013-03-15 送達剤を含む組成物およびその調製 Active JP6356660B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
EP12160742.8 2012-03-22
US201361748844P 2013-01-04 2013-01-04
US61/748,844 2013-01-04
EP13153422.4 2013-01-31
EP13153422 2013-01-31
PCT/EP2013/055363 WO2013139695A1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Publications (3)

Publication Number Publication Date
JP2015515459A JP2015515459A (ja) 2015-05-28
JP2015515459A5 true JP2015515459A5 (enExample) 2016-04-28
JP6356660B2 JP6356660B2 (ja) 2018-07-11

Family

ID=49221869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500854A Active JP6356660B2 (ja) 2012-03-22 2013-03-15 送達剤を含む組成物およびその調製

Country Status (11)

Country Link
US (1) US10335369B2 (enExample)
EP (3) EP3542790B1 (enExample)
JP (1) JP6356660B2 (enExample)
CN (3) CN104203221A (enExample)
ES (1) ES2965469T3 (enExample)
HR (1) HRP20231613T1 (enExample)
HU (1) HUE064694T2 (enExample)
PL (2) PL2827845T3 (enExample)
RS (2) RS58636B1 (enExample)
SI (1) SI2827845T1 (enExample)
WO (1) WO2013139695A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) * 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
ES2929218T3 (es) 2015-01-12 2022-11-28 Enteris Biopharma Inc Formas farmacéuticas orales sólidas
TW201822787A (zh) * 2016-12-30 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 一種glp-1類似物的藥物組成物及其製備方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
BR112020014624A2 (pt) * 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
EP4009958A1 (en) * 2019-08-07 2022-06-15 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP7767264B2 (ja) 2019-09-02 2025-11-11 ノヴォ ノルディスク アー/エス Glp-1ペプチドを含む錠剤を生成するためのプロセス
WO2021043971A1 (en) 2019-09-06 2021-03-11 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
CN114641276A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
JP7777085B2 (ja) * 2020-04-29 2025-11-27 ノヴォ ノルディスク アー/エス Glp-1作動薬およびヒスチジンを含む固形組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN116157143A (zh) * 2020-07-22 2023-05-23 诺和诺德股份有限公司 适合于口服递送的glp-1和gip受体的共激动剂
TW202214679A (zh) * 2020-07-22 2022-04-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及gip受體共促效劑
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
JP2024518058A (ja) 2021-05-07 2024-04-24 イーライ リリー アンド カンパニー 浸食性錠剤
MX2024000768A (es) * 2021-07-15 2024-02-12 Novo Nordisk As Comprimido que comprende una sal del acido n-(8-(2-hidroxibenzoil) amino)caprilico.
JP2024543196A (ja) * 2021-12-01 2024-11-19 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Glp-1及びgip受容体二重アゴニストの医薬組成物並びにその使用
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
NZ219575A (en) 1986-03-12 1990-04-26 Glaxo Group Ltd Phosphate, substituted alkoxy, or amino-carbonyloxy derivatives of milbemycin, and pesticidal compositions
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP2004527518A (ja) 2001-03-27 2004-09-09 ランバクシー ラボラトリーズ リミテッド プラバスタチンの安定薬剤組成物
CA2446957A1 (en) 2001-05-15 2002-11-21 Warner-Lambert Company Llc Compaction process for manufacture of sodium phenytoin dosage form
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20040259952A1 (en) 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
RU2283092C2 (ru) 2002-02-01 2006-09-10 Пфайзер Продактс Инк. Сухие гранулированные композиции азитромицина
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Glp−1分子の投与方法
JP2004131398A (ja) * 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
BRPI0412458A (pt) 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EA013518B1 (ru) 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
EP1750729A2 (en) * 2004-05-06 2007-02-14 Emisphere Technologies, Inc. Solid dosage form of wetted heparin
CA2565188C (en) 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1767818A (zh) 2004-05-31 2006-05-03 三亚药品株式会社 含β-内酰胺抗生素的分散片剂及其制备方法
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
EP1781257B1 (en) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2006060711A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
ES2540929T3 (es) 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006228525A1 (en) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20080255048A1 (en) 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CA2656019C (en) * 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
KR101081149B1 (ko) 2006-09-07 2011-11-07 에미스페어 테크놀로지스, 인코포레이티드 Snac(살카프로제이트 나트륨)의 제조 방법
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
WO2008070543A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
BRPI0808517A2 (pt) 2007-03-02 2014-08-19 Novartis Ag Administração oral de uma calcitonina
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2550363T3 (es) 2007-09-05 2015-11-06 Novo Nordisk A/S Derivados truncados de GLP-1 y su uso terapéutico
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
RU2494755C2 (ru) * 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20110311621A1 (en) 2010-03-16 2011-12-22 Paul Salama Pharmaceutical compositions and methods of delvery
EP2555755B2 (en) 2010-04-07 2019-07-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds

Similar Documents

Publication Publication Date Title
JP2015515459A5 (enExample)
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
JP2015512374A5 (enExample)
RU2470016C2 (ru) Производное бипиразола
HRP20231205T1 (hr) Čvrsti pripravci koji sadrže agonist glp-1, sol n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline i mazivo
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
ES2321012T3 (es) Forma de dosificacion resistente a manipulaciones indebidas, que comprende un adsorbente y un agente adverso.
JP2013199505A5 (enExample)
JP2016519128A5 (enExample)
JP2018504445A5 (enExample)
JP2009500443A5 (enExample)
CA2611520A1 (en) Method and composition for pharmaceutical product
HRP20151383T1 (hr) Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol
RU2016152167A (ru) Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
RU2016122609A (ru) Составы соединений азаиндола
HRP20230075T1 (hr) Čvrsti pripravci namijenjeni oralnoj primjeni
JP2015510916A5 (enExample)
JP2011026348A5 (enExample)
JP2010540547A5 (enExample)
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
EA200901146A1 (ru) Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли
JP2017533220A5 (enExample)
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛